Updated Aug 5, 2026
/Missouri trio charged over alleged Bitcoin kidnapping plot/Japan cabinet secretary affirms Bank of Japan's authority over monetary policy tools/Hut 8 shares slip on mild Q2 revenue miss as AI data center pipeline expands/Hackers Steal More Than $130 Million Through Bug in Coldcard Offline Hardware Wallets/Trump administration tells AI companies no safety testing required for open-weight models/Standard Motor Products targets 11% to 12% adjusted EBITDA margin for 2026/Missouri trio charged over alleged Bitcoin kidnapping plot/Japan cabinet secretary affirms Bank of Japan's authority over monetary policy tools/Hut 8 shares slip on mild Q2 revenue miss as AI data center pipeline expands/Hackers Steal More Than $130 Million Through Bug in Coldcard Offline Hardware Wallets/Trump administration tells AI companies no safety testing required for open-weight models/Standard Motor Products targets 11% to 12% adjusted EBITDA margin for 2026

J&J Bets on Cancer Over Obesity as FDA Clears GSK Antibiotic for Drug-Resistant Infections

Johnson & Johnson will not pursue the obesity drug market, Chief Executive Joaquin Duato said, opting instead to build the company into what he described as the world's leading cancer company. The move sets J&J apart from rivals scrambling…

By Sofia Almeida2 min read
Share